<DOC>
	<DOCNO>NCT02758665</DOCNO>
	<brief_summary>A prospective , open-label , multicentre phase-II trial ibrutinib plus venetoclax plus obinutuzumab physically fit ( CIRS ≤ 6 &amp; normal creatinine clearance ) unfit ( CIRS &gt; 6 &amp; creatinine clearance ≥ 50 ml/min ) patient previously untreated chronic lymphocytic leukemia ( CLL ) TP53 deletion ( 17p- ) and/or mutation</brief_summary>
	<brief_title>Trial Ibrutinib Plus Venetoclax Plus Obinutuzumab Patients With CLL</brief_title>
	<detailed_description>Chronic lymphocytic leukemia ( CLL ) TP53 deletion ( 17p- ) and/or mutation poor prognosis . Different therapeutic strategy test last decade fludarabine-based regimen , alemtuzumab , bendamustine alone rituximab , lenalidomide , ofatumumab , without compel evidence success . For example , FCR regimen standard 1st line treatment fit CLL patient , 5 % ( 1 22 ) patient 17p deletion complete response ( CR ) 40 % patient free disease progression 12 month CLL8 Trial . New agent like Bruton 's Tyrosin Kinase ( BTK ) inhibitor ibrutinib show promising result patient relapsed refractory CLL , however , outcome CLL patient 17p deletion inferior subgroup . The CLL11 trial reveal impressive improvement efficacy GA-101 ( obinutuzumab ) compare rituximab combine Chlorambucil . Moreover , BCL2 antagonist venetoclax ( previously GDC-0199/ABT-199 ) , test single agent relapse / refractory CLL patient , show striking activity tumor lysis syndrome dose limit toxicity . Consequently , current trial test combination regimen consist obinutuzumab , ibrutinib venetoclax ( `` GIVe '' regimen ) first line treatment CLL patient TP53 deletion ( 17p- ) and/or mutation aim demonstrate efficacy population high unmet medical need . The primary objective study evaluate efficacy GIVe regimen patient TP53 deletion ( 17p- ) and/or mutation previously untreated CLL require treatment . For , CR rate cycle 15 ( d1 ; final restaging ) use primary parameter efficacy . The CR rate define proportion patient achieve CR CR incomplete recovery bone marrow ( CRi ) best response ( accord iwCLL criterion ) cycle 15 ( d1 ; final restaging ) start therapy . Efficacy regimen assess evaluation proportion patient free disease progression ( PD-free rate ) 12 cycle therapy , overall response rate ( ORR ) , minimal residual disease ( MRD ) overall survival well time event endpoint outline . A secondary objective study evaluate safety ibrutinib , venetoclax obinutuzumab .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>1 . Have document CLL accord iwCLL criterion , measurable disease ( lymphocytosis &gt; 5x109 and/or palpable measurable lymph node physical exam and/or organomegaly assess physical exam ) 2 . Subjects must untreated CLL , i.e . prior chemotherapy , antibody therapy nonchemotherapeutic agent ( BTK , PI3K , BCL2 inhibitor similar ) . Local irradiation short term ( 1 month ) corticosteroid treatment autoimmune phenomenon allow 3 . Subjects must TP53 deletion ( 17p ) and/or mutation ( bone marrow peripheral blood ) , preexist local test result confirm central laboratory Ulm 4 . CLL require treatment ( `` active disease '' ) accord iwCLL criterion 5 . ECOG ≤ 2 6 . Creatinine clearance ≥ 50 ml/min calculate accord modify formula Cockcroft Gault directly measure 24 h urine collection 7 . Adequate liver function indicate total bilirubin ≤ 2 x , AST , ALT ≤ 3 x institutional ULN value , unless directly attributable patient 's CLL Gilbert 's Syndrome 8 . No cardiovascular disability New York Heart Association ( NYHA ) Class &gt; 2 . Class 2 define comfortability rest moderate physical activity cause dyspnoea , angina pain fatigue 9 . Adequate bone marrow function ( unless directly attributable CLL , BM examination require ) : ANC ≥ 1000/µl ANC &lt; 1000/µl , attributable underlie CLL ( growth factor support may administer screen ) Platelets &gt; 30.000/µl ( unless directly attributable underlie CLL ) Hemoglobin ≥ 8g/dl ( unless directly attributable underlie CLL ) 10 . Negative serological test hepatitis B ( i.e . HBsAg negative antiHBc negative , patient positive antiHBc may include PCR HBV DNA negative ) negative test hepatitisC RNA negative HIV test within 6 week prior registration . [ Patients HBsAg negative/antiHBc positive undetectable serum HBV DNA monitor closely ( every month ) HBV DNA realtime PCR quantification assay low limit detection order 10 WHO IU/mL least 24 month last treatment cycle obinutuzumab . If HBV DNA assay becomes positive , patient preemptively treat nucleoside analogue ( i.e . lamivudine ) 24 month last cycle therapy obinutuzumab refer gastroenterologist management . ] 11 . Age least 18 year 12 . Life expectancy ≥ 6 month 13 . Must able adhere study visit schedule protocol requirement 14 . Able willing provide write informed consent comply study protocol procedures 1 . Transformation CLL ( i.e . Richter 's transformation , prolymphocyctic leukemia ) 2 . One individual organ / system impairment score 4 assessed CIRS definition , exclude Eyes , Ears , Nose , Throat Larynx organ system 3 . Known central nervous system ( CNS ) involvement 4 . Patients history PML 5 . Active malignancy CLL within past 2 year prior study entry , exception : Adequately treat situ carcinoma cervix uteri Adequately treat basal cell carcinoma localize squamous cell carcinoma skin Previous malignancy confine surgically resect ( treated modality ) curative intent remission time screen 6 . Use agent would interfere study drug within 28 day prior registration 7 . Uncontrolled infection require systemic treatment 8 . History severe infusionrelated reaction humanize murine monoclonal antibody , and/ know sensitivity allergy murine product allergy xanthin oxidase rasburicase glucose6phosphate dehydrogenase deficiency 9 . Requires treatment follow drug : Within 7 day prior first dose study drug : No steroid therapy high 20 mg Prednisolone antineoplastic intent ; No CYP3A inhibitor ( e.g . fluconazole , ketoconazole , clarithromycin , warfarin phenprocoumon ) ; No potent CYP3A inducer ( e.g. , rifampin , phenytoin carbamazepine ) ; Within 3 day prior first dose study drug : Grapefruit grapefruit product ; Seville orange ( include marmalade ) ; Star fruit . 10 . History stroke intracranial hemorrhage within 6 month prior registration 11 . Pregnant woman nurse mother 12 . Fertile men woman childbearing potential unless : 1. surgically sterile ≥ 2 year onset menopause 2. willing use two highly effective contraceptive method ( Pearl Index &lt; 1 ) study treatment 18 month end study treatment . 13 . Vaccination live vaccine minimum 28 day prior registration 14 . Legal incapacity 15 . Prisoners subject institutionalized regulatory court order 16 . Persons dependence sponsor investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CLL</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>ibrutinib</keyword>
	<keyword>venetoclax</keyword>
	<keyword>obinutuzumab</keyword>
	<keyword>TP53 Deletion</keyword>
</DOC>